Despite all alternatives, immune checkpoint inhibitors (ICIs) in the treatment of advanced MCC, such as anti-PD-1 inhibitors (pembrolizumab, nivolumab, and retifanlimab) and the anti-PD-L1 inhibitor avelumab, have revolutionized therapies, as they have dramatically improved outcomes for patients with advanced MCC, offering durable responses and better overall survival compared to traditional chemotherapy. The gene discussed is PDCD1; the disease is Merkel cell skin cancer.